Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature
(ELEGANCE Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The ELEGANCE Registry's objective is to collect Real-World Data (RWD), including populations previously not represented in Peripheral Vascular Disease (PVD) trials, health economics data, and to support the safe use of commercially available Boston Scientific Corporation (BSC) drug-eluting devices for the treatment of lesions located in the peripheral vasculature.
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive treatment with commercially available drug-eluting devices for lesions in the peripheral vasculature
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessments such as Quality of Life questionnaires and six-minute walk test
Extended Follow-up
Participants in China will continue follow-up assessments for an additional 3 years
What Are the Treatments Tested in This Trial?
Interventions
- Boston Scientific Corporation (BSC) drug-eluting device
Find a Clinic Near You
Who Is Running the Clinical Trial?
Boston Scientific Corporation
Lead Sponsor
Michael F. Mahoney
Boston Scientific Corporation
Chief Executive Officer since 2016
MBA from Wake Forest University, BBA in Finance from the University of Iowa
Kenneth Stein
Boston Scientific Corporation
Chief Medical Officer since 2020
MD from Harvard Medical School, MMSc in Clinical Investigation from Harvard-MIT Division of Health Sciences and Technology